🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 22 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/08/2001 44,10 47,16 43,50 47,16 +5,93% 8,30% 11.917
30/08/2001 47,40 47,46 43,38 44,52 -6,08% 8,61% 19.733
29/08/2001 48,60 48,96 46,80 47,40 -2,59% 4,44% 16.850
28/08/2001 49,80 49,80 46,98 48,66 -2,29% 5,66% 20.517
27/08/2001 48,66 50,04 48,54 49,80 +0,97% 3,08% 24.800
24/08/2001 50,34 50,34 48,66 49,32 -0,96% 3,34% 14.617
23/08/2001 47,58 50,34 47,52 49,80 +3,23% 5,93% 37.217
22/08/2001 49,20 50,88 48,00 48,24 -2,19% 5,85% 19.683
21/08/2001 49,68 51,00 48,00 49,32 -0,24% 6,04% 27.650
20/08/2001 50,40 52,50 49,20 49,44 -3,63% 6,55% 11.983
17/08/2001 54,06 54,66 50,16 51,30 -6,04% 8,32% 21.050
16/08/2001 56,34 56,76 53,64 54,60 -3,40% 5,54% 8.467
15/08/2001 57,00 57,18 56,10 56,52 -1,36% 1,89% 8.567
14/08/2001 57,30 57,30 56,64 57,30 +0,21% 1,15% 10.167
13/08/2001 57,60 57,60 56,10 57,18 -0,21% 2,60% 37.200
10/08/2001 57,90 57,90 55,80 57,30 -0,52% 3,63% 9.300
09/08/2001 56,70 58,20 56,70 57,60 +0,84% 2,65% 3.617
08/08/2001 59,52 59,52 56,70 57,12 -4,61% 4,74% 11.767
07/08/2001 59,58 59,88 54,36 59,88 +1,32% 9,26% 14.633
06/08/2001 61,56 63,00 57,90 59,10 -5,29% 8,28% 13.417
03/08/2001 62,94 62,94 60,00 62,40 -0,48% 4,67% 20.700
02/08/2001 61,08 66,00 60,78 62,70 +0,48% 8,55% 48.117
01/08/2001 61,08 62,40 58,56 62,40 +1,96% 6,29% 35.467
31/07/2001 53,28 61,50 53,28 61,20 +14,35% 15,43% 60.700
30/07/2001 53,40 54,00 52,74 53,52 -0,34% 2,36% 3.833
27/07/2001 54,00 54,30 52,80 53,70 -0,33% 2,78% 7.933
26/07/2001 51,78 53,94 51,78 53,88 +4,18% 4,17% 13.133
25/07/2001 51,00 52,20 50,40 51,72 +1,41% 3,53% 6.183
24/07/2001 49,56 51,00 49,50 51,00 +0,00% 3,03% 6.683
23/07/2001 52,68 52,68 49,50 51,00 -2,07% 6,04% 6.533